R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma

Xiao-Hui He1, Bo Li1, Sheng Yang1, Ning Lu2, Xun Zhang2, Shuang-Mei Zou2, Ye-Xiong Li3, Yong-Wen Song3, Shan Zheng3, Mei Dong1, Sheng-Yu Zhou1, Jian-Liang Yang1, Peng Liu1, Chang-Gong Zhang1, Yan Qin1, Feng-Yi Feng1 and Yuan-Kai Shi1

Abstract

To further explore the role of rituximab when added to the CHOP-like regimen in the treatment of immunohistochemically defined non-germinal center B-cell subtype (non-GCB) diffuse large B-cell lymphoma (DLBCL), 159 newly diagnosed DLBCL patients were studied retrospectively based on the immunohistochemical evaluation of CD10, Bcl-6, MUM-1, and Bcl-2. Altogether, 110 patients underwent the CHOP-like regimen, and rituximab was added for the other 49 patients. Cox regression analysis showed that compared with the CHOP-like regimen, the rituximab-based regimen (R-CHOP regimen) significantly decreased the risk of disease relapse and progression in CD10-negative patients (P = 0.001), Bcl-6-negative patients (P = 0.01), and MUM-1-positive patients (P = 0.003). The risk of disease relapse in patients with non-GCB subtype (P = 0.002) also decreased. In contrast, patients with the opposite immunohistochemical marker expression profile and GCB subtype did not benefit from treatment with the R-CHOP regimen. In addition, non-GCB subtype patients had a significantly higher expression rate of Bcl-2 than GCB subtype patients (P = 0.042). Although univariate analysis found that both Bcl-2-positive and -negative patients had significantly higher event-free survival rates with the R-CHOP regimen, only Bcl-2 positivity (P = 0.004) maintained significance in the Cox regression analysis. We conclude that the addition of rituximab can significantly improve the prognosis of patients with non-GCB subtype DLBCL, which is closely related to the expression of CD10, Bcl-6, MUM-1, and Bcl-2.

Key words Diffuse large B-cell lymphoma, rituximab, chemotherapy, NF-κB, immunohistochemistry

Diffuse large B-cell lymphomas (DLBCLs), which represent approximately 40% of adult non-Hodgkin’s lymphomas (NHLs), are a heterogeneous group of tumors that vary in immunophenotype, cytogenetics, and clinical features[11]. Gene expression profiling has revealed that DLBCL can be subdivided into three groups:
anthracycline-based regimen\(^\text{[2-5]}\). However, some retrospective studies found that patients with non-GCB subtype DLBCL can have comparable long-term survival to those with GCB subtype DLBCL when treated with rituximab-based chemotherapy\(^\text{[6,7]}\).

To further explore the role of rituximab in the treatment of non-GCB subtype DLBCL, clinical data from 159 DLBCL patients were analyzed retrospectively based on four popular markers: CD10, Bcl-6, MUM-1, and Bcl-2.

### Materials and Methods

#### Patients and clinical data collection

Clinical data were collected from the database of the Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC). Patients with primary DLBCL who were treated in our hospital and had immunostaining performed for at least one of the following proteins were eligible for the study: CD10, Bcl-6, MUM-1, and Bcl-2. The study protocol and sampling were approved by the Institutional Review Board of the Cancer Institute and Hospital of CAMS & PUMC. Informed consent was provided according to the Declaration of Helsinki. Clinical data were obtained at the time of diagnosis. Staging was performed according to the Ann Arbor staging system for Hodgkin’s disease. At the time of diagnosis, each patient underwent a physical examination, a full blood count and biochemical profile analysis, serum lactate dehydrogenase (LDH) detection, chest X-ray, bone marrow aspiration, ultrasonography, and computed tomography or magnetic resonance imaging (MRI) scan. B symptoms were defined as fever of unknown reason (>38°C) for more than 3 days, more than 10% weight loss within 6 months, and night sweats. Bulky disease was defined as a tumor mass larger than 10 cm.

#### Treatment

At least six cycles of CHOP-like regimens, including the CHOP regimen (cyclophosphamide, vincristine, doxorubicin/epirubicin, and prednisone), etoposide added to the CHOP regimen, HyperCVAD regimen (fractionated cyclophosphamide, vincristine, epirubicin, and dexamethasone), BACOP regimen (bleomycin, doxorubicin/epirubicin, cyclophosphamide, vincristine, and prednisone), and CHEP regimen (cyclophosphamide, etoposide, epirubicin, and prednisone), were given to each patient. If rituximab (Roche, Basel, Swiss) was added to the regimen, it was administered the day before the start of chemotherapy at a dose of 375 mg/m\(^2\) and repeated every 3 weeks. Locoregional radiotherapy was added for patients with stage I/II disease or bulky disease.

#### Patient following-up

Each patient was followed every 3 months for the first 2 years and every 6 months for the next 3 years till April 2011. Full blood count, biochemical profile analysis, ultrasonography, and computed tomography or MRI were conducted each time.

#### Immunohistochemical study

All tumor specimens were obtained by biopsy or surgical resection, fixed in 10% buffered formaldehyde, and embedded in paraffin. Immunohistochemical analysis with antibodies against CD20 (clone L26, Novocastra, Newcastle, UK), CD79a (clone HM57, Darko, Glostrup, Denmark), CD3 (clone SP7, Novocastra, Newcastle, UK), CD5 (clone 4C7, Zymed, San Diego, USA), and CD45RO (clone UCHL-1, Novocastra, Newcastle, UK) was conducted. All specimens were reviewed separately by two experienced pathologists, and a common consensus was reached in all cases. The WHO diagnostic criteria for NHL were adopted for diagnosis. Furthermore, CD10 (clone 56C6, Novocastra, Newcastle, UK), Bcl-6 (clone PG-B6p, Novocastra, Newcastle, UK), MUM-1 (clone MUM1p, Dako, Glostrup, Denmark), and Bcl-2 (clone 100-D5, Novocastra, Newcastle, UK) were tested upon clinical request. Cases were considered positive if 30% or more of tumor cells were stained with an antibody. Subtype determination was based on the algorithm developed by Hans \(^\text{[4]}\).

#### Statistical analysis

SPSS 10.0 software was used for data analysis. Overall survival (OS) was estimated using the Kaplan-Meier method from the day of diagnosis to death or to the date of the last follow-up. Event-free survival (EFS) was estimated from the day of diagnosis to the time of disease progression or relapse or to the date of the last follow-up visit. The log-rank test was used to compare survival curves. For continuous variables, the t test or Mann-Whitney U test was employed to analyze the difference between two groups. \(\chi^2\) test was used to analyze categorical variables. All statistical analyses used 0.05 as the significance level (two-sided test).

### Results

#### Patient characteristics

A total of 159 DLBCL patients, aged from 14 to 83
years (median, 50), were eligible for this retrospective analysis: 118 were treated with the CHOP regimen, 24 with etoposide added to the CHOP regimen, 8 with the BACOP regimen, 6 with the HyperCVAD regimen, and 3 with the CHEP regimen; rituximab was added to the CHOP regimen (R-CHOP regimen) in 49 cases. Patient characteristics are summarized in Table 1. The proportion of patients with a higher IPI score (high/ high-intermediate risk) was significantly greater in patients treated with the R-CHOP regimen than in those treated with the CHOP-like regimen (26.5% vs. 14.5%; \( P = 0.037 \)); no differences in other factors were observed between these two groups (Table 1).

**Relationships between survival and clinical factors**

The median follow-up time was 24 months (range, 1 to 105 months) for the whole group. The 2-year EFS and OS rates were 53.2% and 72.8%, respectively. In patients treated with the CHOP-like regimen, univariate analysis found that B symptoms, elevated \(B\)-lymphocyte, and patients with higher IPI score were associated with significantly lower 2-year EFS and 2-year OS rates; bulky disease was also associated with lower 2-year EFS rate (Table 2). Although more patients had a higher IPI score, the group treated with the R-CHOP regimen still showed significantly higher 2-year EFS rate (75.8% vs. 42.2%, \( P < 0.001 \)) and OS rate (81.8% vs. 68.7%, \( P = 0.035 \)) compared with the group treated with the CHOP-like regimen. Among patients treated with the CHOP-like regimen, no significant differences were observed between GCB and non-GCB subtypes (\( P > 0.05 \)). Further analysis showed that almost all subgroup patients had significantly higher EFS rates when treated with the R-CHOP regimen, with the exception of patients with elevated \(B\)-lymphocyte levels and those who were older than 60 (Table 3). In terms of OS, only patients with a higher IPI score and without B symptoms benefited from treatment with the R-CHOP regimen. This result was most likely due to a relatively short follow-up period.

**Immunohistochemistry**

Immunohistochemistry of Bcl-2 was performed on 110 specimens, CD10 on 134 patients, Bcl-6 on 135 specimens, and MUM-1 on 137 specimens. The positive rate was 63.6% for Bcl-2, 20.1% for CD10, 34.8% for Bcl-6, and 80.3% for MUM-1. According to the algorithm

---

**Table 1. Clinical characteristics of 159 patients with diffuse large B-cell lymphoma (DLBCL)**

| Variate               | Total [cases (%)] | Treatment [cases (%)] | \( P \) | Subtype [cases (%)] | \( P \) |
|-----------------------|-------------------|-----------------------|---------|---------------------|---------|
|                       |                   | CHOP-like regimen     | Rituximab-based regimen |         | GCB [cases (%)]     |         |
|                       |                   |                       |                     |         | Non-GCB [cases (%)] |         |
| Total                 | 159(100)          | 110(69.2)             | 49(30.8)             | 0.160   | 33(25.6)            | 0.750   |
| Age (years)           |                   |                       |                     |         |                     |         |
| \(< 60\)              | 117(73.6)         | 84(76.4)              | 33(76.3)             |         | 24(27.3)            |         |
| \(\geq 60\)           | 42(26.4)          | 26(33.3)              | 16(32.7)             |         | 9(18.8)             |         |
| Sex                   |                   |                       |                     | 0.320   |                     | 0.021   |
| Male                  | 92(57.9)          | 66(66.7)              | 26(75.8)             |         | 22(66.7)            |         |
| Female                | 67(42.1)          | 44(33.3)              | 23(42.6)             |         | 11(41.1)            |         |
| B symptoms            |                   |                       |                     | 0.140   |                     | 0.025   |
| Present               | 36(22.6)          | 22(66.7)              | 14(33.3)             |         | 5(14.3)             |         |
| Absent                | 123(77.4)         | 88(66.7)              | 35(66.7)             |         | 28(85.7)            |         |
| IPI                   |                   |                       |                     | 0.037   |                     | 0.005   |
| Low/low-intermediate  | 130(81.8)         | 94(74.1)              | 36(75.9)             |         | 31(91.9)            |         |
| High/high-intermediate| 29(18.2)          | 16(53.6)              | 13(14.3)             |         | 2(6.6)              |         |
| Bulky disease         |                   |                       |                     | 0.380   |                     | 0.650   |
| Present               | 18(11.3)          | 11(61.1)              | 7(39.4)              |         | 4(22.2)             |         |
| Absent                | 141(88.7)         | 99(68.0)              | 42(60.6)             |         | 29(77.8)            |         |
| \(B\)-microglobulin elevation | 49(30.8) | 34(69.4) | 15(30.6) |         | 11(33.3) | 34(35.4) |
| Present               |                   |                       |                     | 0.005   |                     | 0.770   |
| Absent                | 110(69.2)         | 76(68.1)              | 34(69.4)             |         | 22(66.7)            |         |

*In total, 129 patients have complete data for subtype classification. According to the algorithm developed by Hans et al., 74.4% (96/129) of patients were classified with non-GCB subtype disease. IPI, international prognostic index; GCB, germinal center B-cell-like; non-GCB, non-germinal center B-cell-like.*
developed by Hans et al.\textsuperscript{[4]}, 74.4% (96/129) of patients were classified as non-GCB subtype.

In terms of the relationship between immuno-histochemical markers, the positive rate of Bcl-2 was significantly higher in MUM-1-positive patients than in MUM-1-negative patients (73.6% vs. 35.7%, \( P < 0.001 \)) and higher in patients with non-GCB subtype disease than in those with GCB subtype disease (68.4% vs. 53.8%, \( P = 0.042 \)).

Survival analysis of patients treated with the CHOP-like regimen showed that the expression of Bcl-2 and MUM-1 indicated a poorer prognosis (Figures 1A and 1B). The 2-year EFS rate was significantly lower in patients with Bcl-2 (33.0% vs. 69.0%, \( P = 0.005 \)) or MUM-1 expression (38.0% vs. 65.6%, \( P = 0.018 \)) than in those without marker expression. CD10 and Bcl-6 did not show prognostic value in EFS (Figures 1C and 1D).

There was no significant difference in either EFS (\( P = 0.46 \)) or OS (\( P = 0.79 \)) between GCB and non-GCB subtype patients.

As shown in Table 3, compared with the CHOP-like regimen, the R-CHOP regimen improved survival in selected populations. The R-CHOP regimen significantly improved 2-year EFS rate in CD10-negative, Bcl-6-negative, and MUM-1-positive patients (all \( P < 0.01 \)). Accordingly, patients with the non-GCB subtype disease obtained more benefit from treatment with the R-CHOP regimen than GCB subtype patients (\( P = 0.002 \)). For CD10-positive patients, Bcl-6-positive patients, MUM-1-negative patients, and patients with the GCB subtype disease, the R-CHOP regimen did not show a significant difference in EFS improvement compared with the CHOP-like regimen. In terms of Bcl-2 status, both Bcl-2-positive and -negative patients achieved significantly

### Table 2. Univariate prognostic analysis on patients with DLBCL treated with the CHOP-like regimen

| Variate | 2-year EFS rate (%) | \( P \) | 2-year OS rate (%) | \( P \) |
|---------|---------------------|--------|-------------------|--------|
| Age (years) | | 0.083 | | 0.810 |
| < 60 | 36.9 | | 69.1 | |
| \( \geq 60 \) | 58.7 | | 67.7 | |
| Sex | | 0.930 | | 0.530 |
| Male | 40.0 | | 69.9 | |
| Female | 44.8 | | 66.7 | |
| B symptoms | | <0.001 | | 0.002 |
| Present | 15.7 | | 47.4 | |
| Absent | 49.4 | | 75.7 | |
| IPI | | <0.001 | | <0.001 |
| Low/low-intermediate | 0 | | 0 | |
| High/high-intermediate | 57.4 | | 82.8 | |
| Bulky disease | | 0.033 | | 0.160 |
| Present | 10.9 | | 51.1 | |
| Absent | 45.9 | | 70.7 | |
| \( \beta2 \)-microglobulin elevation | | <0.001 | | 0.002 |
| Present | 30.0 | | 55.0 | |
| Absent | 63.0 | | 78.9 | |
| Bcl-2 expression | | 0.005 | | 0.090 |
| Positive | 32.8 | | 63.9 | |
| Negative | 69.9 | | 81.8 | |
| CD10 expression | | 0.640 | | 0.950 |
| Positive | 41.6 | | 69.3 | |
| Negative | 41.2 | | 67.6 | |
| Bcl-6 expression | | 0.180 | | 0.810 |
| Positive | 54.0 | | 67.8 | |
| Negative | 36.1 | | 68.3 | |
| MUM-1 expression | | 0.018 | | 0.130 |
| Positive | 38.4 | | 71.5 | |
| Negative | 65.6 | | 81.8 | |

EFS, event-free survival; OS, overall survival. Other abbreviations as in Table 1.
higher 2-year EFS from treatment with the R-CHOP regimen than from treatment with the CHOP-like regimen (both $P < 0.05$). In regard to OS, the difference was marginal in Bcl-2-positive patients ($P = 0.053$) and significant in CD10-negative ($P = 0.038$) and Bcl-6-negative patients ($P = 0.025$). However, the difference in MUM-1-positive patients was not significant.

Cox regression analysis further showed that the R-CHOP regimen significantly decreased the risk of disease relapse or progression in Bcl-2-positive patients ($P = 0.004$), CD10-negative patients ($P = 0.001$), Bcl-6-negative patients ($P = 0.01$), MUM-1-positive patients ($P = 0.003$), and patients with non-GCB subtype disease ($P = 0.002$) (Table 4). However, for patients with the opposite expression profile and patients with GCB subtype disease, the R-CHOP regimen showed no effect on the risk of disease relapse and progression (data not shown).

**Discussion**

DLBCL is the most common subtype of NHL and accounts for approximately 40% of NHL patients\(^{11}\). Gene expression profiling revealed that DLBCL can be subdivided into GCB and non-GCB subtypes\(^{2,3}\). Many retrospective studies have found that non-GCB subtype patients have significantly lower survival rates than GCB
subtype patients when treated with a CHOP-like regimen\textsuperscript{[22,25]}. Therefore, a more effective regimen should be used to improve the survival of non-GCB subtype DLBCL patients. Nyman et al.\textsuperscript{[6]} found that a R-CHOP regimen could eliminate the prognostic value of immunohistochemically defined GCB and non-GCB phenotypes in DLBCL. It was thus suggested that the R-CHOP regimen might significantly improve the prognosis of non-GCB subtype patients, making their survival comparable with GCB subtype patients.

To further explore this hypothesis, clinical data from 159 patients with newly diagnosed DLBCL were analyzed based on immunohistochemical examination of CD10, Bcl-6, MUM-1, and Bcl-2. Unfortunately, because the survival difference between non-GCB and GCB subtype patients did not reach a significant level in our study, the results of the Finland study\textsuperscript{[6]} could not be reproduced. However, based on our survival analysis, we found that only non-GCB subtype patients benefited from treatment with the R-CHOP regimen, leading to significantly improved EFS. In GCB subtype patients, EFS was comparable between the R-CHOP regimen group and the CHOP-like regimen group. These results are similar to those of the Finland study, which indicated that the R-CHOP regimen is an effective way to improve the prognosis of non-GCB subtype patients. Furthermore, we also found that only CD10-negative patients, Bcl-6-negative patients, and MUM-1-positive patients benefited from treatment with the R-CHOP regimen, whereas patients with the opposite expression profile did not. These results were further validated by Cox regression analysis, which showed that the R-CHOP regimen only decreased the risk of disease relapse or progression in CD10-negative patients, Bcl-6-negative patients, MUM-1-positive patients, and patients with non-GCB subtype disease. In addition, Cox regression analysis proved that R-CHOP regimen decreased the risk of disease relapse or progression only in Bcl-2-positive patients, although both Bcl-2-positive and -negative patients were found to have a significantly higher EFS from treatment with the R-CHOP regimen in the univariate analysis. These interesting clinical findings indicate that rituximab has the ability to improve survival of non-GCB subtype patients, and this ability most likely correlates with the expression of the previously mentioned immunohistochemical markers.

CD10 is a cell surface marker that is expressed in many types of cells, including DLBCL\textsuperscript{[8-11]}. Bcl-6 is a transcription suppressor that can inhibit lymphocyte activation and the differentiation of germinal center B cells to plasma cells\textsuperscript{[15-18, 19, 22-24]}. Both CD10 and Bcl-6 have been found to be associated with increased apoptosis in B-cell lymphomas when overexpressed\textsuperscript{[16,17]}. However, the definitive mechanism by which apoptosis is induced by CD10 and Bcl-6 is still unclear. Some studies have indicated that the Fas ligand signaling pathway may be involved because the expression of CD10 and Bcl-6 showed a significant positive correlation with the expression of Bid, Bak, and Bax and a negative correlation with the expression of Bcl-xL\textsuperscript{[19-21, 24]}. In addition, the expression of Bcl-6 was negatively correlated with Bcl-2 expression\textsuperscript{[19-21, 24]}. Therefore, it was suggested that the loss of CD10 and/or Bcl-6 expression might induce activation of the anti-apoptosis pathway concerning Bcl-2 family members. Because the overexpression of Bcl-2 family members can be suppressed by rituximab, it is reasonable that CD10-negative patients and Bcl-6-negative patients may benefit from treatment with a rituximab-based chemotherapy\textsuperscript{[22,24]}

As shown in the present study, the EFS and OS

| Table 4. Multivariate Cox regression prognostic analysis on the EFS of selective populations |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variate                  | Bcl-2-positive | CD10-negative | Bcl-6-negative | MUM-1-positive | Non-GCB subtype |
| RR | 95% CI | P | RR | 95% CI | P | RR | 95% CI | P | RR | 95% CI | P | RR | 95% CI | P |
| B symptoms | | | | | | | | | | | | | | |
| Present vs. absent | 4.0 | 1.4-11.7 | 0.011 | 2.6 | 1.1-6.3 | 0.038 | 1.9 | 0.84-4.2 | 0.120 | 2.6 | 1.1-6.1 | 0.026 | 2.6 | 1.2-5.9 | 0.022 |
| IPI | | | | | | | | | | | | | | |
| High/high-intermediate vs. low/low-intermediate | 2.8 | 0.98-7.8 | 0.056 | 2.1 | 0.86-5.3 | 0.100 | 2.8 | 1.1-7.4 | 0.038 | 2.5 | 0.96-6.4 | 0.060 | 1.8 | 0.67-4.6 | 0.250 |
| Bulky disease | | | | | | | | | | | | | | |
| Present vs. absent | 0.77 | 0.17-3.5 | 0.730 | 0.72 0.21-2.5 | 0.610 | 1.2 | 0.33-4.2 | 0.790 | 1.2 | 0.37-3.7 | 0.800 | 1.3 | 0.41-3.9 | 0.690 |
| β2-microglobulin elevation | | | | | | | | | | | | | | |
| Present vs. absent | 2.1 | 0.85-4.9 | 0.110 | 2.4 | 1.1-4.9 | 0.021 | 2.1 | 0.89-4.9 | 0.088 | 3.9 | 1.6-9.2 | 0.002 | 3.2 | 1.5-6.9 | 0.003 |
| Treatment | CHOP vs. R-CHOP | 4.9 | 1.7-14.6 | 0.004 | 4.6 | 1.9-10.9 | 0.001 | 4.1 | 1.4-11.8 | 0.010 | 4.8 | 1.7-13.3 | 0.003 | 4.2 | 1.7-10.5 | 0.002 |

RR, risk ratio; CI, confidence interval. Other abbreviations as in Tables 1 and 2.
rates of the patients with CD10-negative or Bcl-6-negative tumors were significantly improved by the R-CHOP regimen. For CD10-positive and Bcl-6-positive patients, however, the R-CHOP regimen did not improve survival compared with the CHOP-like regimen alone. This outcome is most likely due to the tendency of self-apoptosis to occur in CD10- and Bcl-6-positive tumor cells because the CHOP-like regimen alone is effective enough to induce apoptosis and there is no need for the addition of rituximab.

MUM-1 is a transcription factor that is required for the proliferation of B and T lymphocytes and is induced by the binding of c-Rel to NF-κB motifs in its promoter\[25\]. It is also a potential mediator of NF-κB proliferative responses\[26\]. Given its biologic function, the expression of MUM-1 is a strong indicator of NF-κB activation. Furthermore, as shown in our study, the positive rate of Bcl-2 was significantly higher in MUM-1-positive patients than in MUM-1-negative patients. Because many studies have found that Bcl-2 and other Bcl-2 family members are target genes in the NF-κB pathway, the overexpression of Bcl-2 family members may provide other evidence of NF-κB pathway activation\[27-31\]. Some in vitro studies have found that rituximab has a dual suppression effect on both NF-κB activation and Bcl-2 overexpression\[10-14\], which would explain the results in our study demonstrating that the R-CHOP regimen can significantly improve the EFS of MUM-1-positive patients.

Bcl-2 is an important anti-apoptotic factor in normal B-cell development and differentiation. According to our analysis, it appears that Bcl-2 is closely associated with the expression of all three markers mentioned above. The overexpression of Bcl-2 is more likely to occur in CD10-negative, Bcl-6-negative, and MUM-1-positive patients, which is the typical expression pattern in non-GCB subtype patients. This result is in accordance with Bcl-2 expression being significantly higher in non-GCB subtype patients in our study. For ABC...
subtype DLBCL patients, many studies have indicated that the constitutive activation of the NF-κB pathway appears to be responsible for Bcl-2 overexpression [32]. Moreover, 18q21 amplification was also found to be frequently detected in ABC subtype DLBCL patients [33]. For type 3 patients, the mechanism is unknown. Because gene expression profiling showed that these patients had lower expression levels of MUM-1, it has been suggested that some mechanisms other than NF-κB pathway activation might be involved in Bcl-2 overexpression.

Some in vitro studies have found that rituximab can sensitize lymphoma cells to chemotherapeutic drugs via down-regulating Bcl-2 family members [23] [34]. In addition, clinical studies conducted by Mounier et al. [35] in elderly DLBCL patients proved that rituximab-based chemotherapy can significantly improve the survival of Bcl-2-positive patients. Although the same result was not reproduced in our elderly population due to the smaller number of cases (n = 21, P = 0.180), we demonstrated the efficacy of rituximab on Bcl-2-positive patients when the Cox regression analysis was conducted among the entire group of patients (P = 0.004) and among patients younger than 60 (P = 0.008). Therefore, Bcl-2 overexpression itself is the strongest indication for the addition of rituximab, no matter what type of mechanism is involved. Additionally, these results further validate the survival improvement ability of rituximab in non-GCB subtype patients, which may be exerted by either directly inhibiting the enhanced function of Bcl-2 or inhibiting another pathway that could induce the enhanced function of Bcl-2, such as NF-κB pathway activation.

In conclusion, the addition of rituximab to the CHOP-like regimen can significantly improve the prognosis of non-GCB subtype DLBCL patients. Suppressing the constitutive activation of the NF-κB pathway and/or perturbing Bcl-2-related anti-apoptotic proteins may be responsible. In addition, as shown in our study, not only non-GCB subtype DLBCL patients but also CD10-negative patients, Bcl-6-negative patients, MUM-1-positive patients, and Bcl-2-positive patients can benefit from treatment with rituximab. This result suggests that some GCB subtype patients, such as CD10-positive/Bcl-6-negative/MUM-1-negative patients and CD10-negative/Bcl-6-positive/MUM-1-negative patients, may be qualify for rituximab-based chemotherapy. This theory has been confirmed by preliminary results in the literature showing that not only non-GCB DLBCL patients but also GCB patients may benefit from rituximab-based chemotherapy [36,37]. However, the number of patients with those two expression modes was too small in our study, making further analysis impossible. Studies concerning this issue are needed, which could increase the target population of rituximab-based chemotherapy.

Received: 2011-11-14; revised: 2012-03-05; accepted: 2012-03-14.

References

[1] Coffier B. Diffuse large cell lymphoma. Curr Opin Oncol, 2001;13:325–334.
[2] Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000;403:503–511.
[3] Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 2002;346:1937–1947.
[4] Hana CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004;103:275–282.
[5] Muir JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B-cell lymphoma. J Pathol, 2006;208:714–723.
[6] Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood, 2007;109:4930–4935.
[7] Seki R, Onshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci, 2009;100:1842–1847.
[8] Fang JM, Finn WG, Husson JW, et al. CD10 antigen expression correlates with the t(14;18)(q32;q21) major break-point region in diffuse large B-cell lymphoma. Mod Pathol, 1999;12:296–300.
[9] Cutrona G, Leanza N, Ulivi M, et al. Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood, 1999;94:3067–3076.
[10] Dogan A, Bagdi E, Munson P, et al. CD10 and Bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol, 2000;24:846–852.
[11] King BE, Chen C, Locker J, et al. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. Mod Pathol, 2000;13:1219–1231.
[12] Dent AL, Shaffer AL, Yu X, et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science, 1997;276:589–592.
[13] Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet, 1997;16:161–170.
[14] Dent AL, Vasanwala FH, Toney LM. Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev Oncol Hematol, 2002;41:1–9.
[15] Cutrona G, Tasso P, Dono M, et al. CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. Br J Cancer, 2002;86:1776–1785.
[16] Bai M, Agnantis NJ, Skyrlas A, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
Mod Pathol, 2003, 16:471–480.

[17] Morabito F, Mangiola M, Raperetti D, et al. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica, 2003, 88:864–873.

[18] Bai M, Skrylas A, Agranits NJ, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol, 2004, 17:847–856.

[19] Kojima Y, Tsurumi H, Goto N, et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol, 2006, 76:465–472.

[20] Tang TT, Dowlbenko D, Jackson A, et al. The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem, 2002, 277:14255–14265.

[21] Yamochi T, Kaneita Y, Akiyama T, et al. Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X (L). Oncogene, 1999, 18:487–494.

[22] Jazirehi AR, Huerta-Yepes S, Cheng G, et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res, 2005, 65:264–276.

[23] Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene, 2005, 24:2121–2143.

[24] Vega MI, Jazirehi AR, Huerta-Yepes S, et al. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin’s lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol, 2005, 175:2174 – 2183.

[25] Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med, 2000, 191:1281–1292.

[26] Mitrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIIRF/IRF4 for mature B and T lymphocyte function. Science, 1997, 275:540–543.

[27] Wang CY, Guttridge DC, Mayo MW, et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol, 1999, 19:5923–5929.

[28] Grossmann M, O’Reilly LA, Gugasyan R, et al. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J, 2000, 19:6351–6360.

[29] Li J, Peet GW, Balzarano D, et al. Novel NEMO/kappaB kinase and NF-kappaB target genes at the pre-B to immature B cell transition. J Biol Chem, 2001, 276:18579–18590.

[30] Grumont RJ, Rouire IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev, 1999, 13:400–411.

[31] Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem, 1996, 271:27201–27204.

[32] Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med, 2001, 194:1861–1874.

[33] Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:961–966.

[34] Mounier N, Briere J, Gisselbrecht C, et al. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica, 2006, 91:715–716.

[35] Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood, 2003, 101:4279–4284.

[36] Xia ZG, Xu ZZ, Zhao WL, et al. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol, 2010, 89:171–177.

[37] Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol, 2008, 26:4587–4594.